Die Information für Ärzte und Apotheker
Neutral, unabhängig und anzeigenfrei

STARTSEITE
Current issue
Archives
Impressum
Datenschutz
 
 
arznei-telegramm®  12/2017

SPOT ON
SPRINT study on more intensive blood pressure treatment … significant questions still unsolved, first guidelines modified
ORBITA trial – last nail in the coffin for PCI in stable angina?

NEW ON THE MARKET
Cladribine (MAVENCLAD) for multiple sclerosis

BEWARE MISINFORMATION
VIRUPROTECT and ALGOVIR against colds?

IN BRIEF
No pain medication against uncomplicated cystitis
Once again: teriparatide (FORSTEO) against osteoporosis

CURRENT ADR NETWORK REPORT
Ethinyl estradiol + dienogest (VALETTE, generics) frequently prescribed despite unclear risk of thromboembolism

SIDE EFFECTS
Anaphylaxis with iron isomaltoside (MONOFER)
Hypersexuality with donepezil (ARICEPT, generics)
Fatal arrhythmia and other adverse effects with fingolimod (GILENYA)

e a-t ON THE INTERNET
Particularly drugs with a small or no additional benefit are advertised
Libido pill flibanserin (USA: ADDYI) – a billion dollar flop


© arznei-telegramm